Congratulations to Dr. Adam Straub who was recently awarded a new NHLBI R35. Dr. Straub has been awarded annual direct costs of over $600,000 for his grant titled, “Basic and Translational Studies in Redox Regulation of Cardiovascular Physiology and Disease.” This proposal was submitted in response to the competitive funding opportunity titled NHLBI Emerging Investigator Award (EIA) under funding opportunity number RFA-HL-20-012.
Cytochrome b5 reductase 3 (CYB5R3) serves as a critical redox switch for substrates such as heme and coenzyme Q that are needed for controlling of biogas molecules such as nitric oxide and oxygen. Building on our currently funded NHLBI studies and published results, we aim to 1) improve our understanding of basic redox biology through work involving other CYB5R family members, 2) gain insight into unidentified and novel redox partners and substrates of CYB5R enzymes, 3) uncover the translational impact of CYB5R enzymes in human disease and 4) discover new small molecule drugs that restore redox signaling and reverse cardiovascular disease. As such, this proposal may lend critical new insight into novel targets, better strategies, and new drugs to improve the health of people living with cardiovascular disease.